Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or death
Authors: Indranil Dasgupta, Ajay K. Singh
Journal: Annals of Internal Medicine (2017)

ACP Journal Club17 October 2017Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or deathIndranil Dasgupta, MBBS, MD, DM, FRCP, Ajay K. Singh, MBBS, FRCP, MBAIndranil Dasgupta, MBBS, MD, DM, FRCPHeartlands Hospital and University of Birmingham, Birmingham, England, UK (I.D.)Search for more papers by this author, Ajay K. Singh, MBBS, FRCP, MBAHarvard Medical School, Boston, Massachusetts, USA (A.K.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2017-167-8-047 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationRuospo M, Saglimbene VM, Palmer SC, et al. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev. 2017;6:CD010137. https://pubmed.ncbi.nlm.nih.gov/28594069Clinical Impact RatingsGIM/FP/GP: Endocrinology: Nephrology: References1 GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459-544. [PMID: 27733281] Google Scholar2 United States Renal Data System. 2016 USRDS annual data report: Epidemiology of kidney disease in the United States. Volume 2, chapter 1: incidence, prevalence, patient characteristics, and treatment modalities. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2016. www.usrds.org/2016/view/v2_01.aspx (accessed 14 Aug 2017). Google Scholar3 Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-22. [PMID: 27295427] Google Scholar4 Wanner C, Inzucchi SE, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323-34. [PMID: 27299675] Google Scholar5 Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i717. [PMID: 26920333] Google Scholar Author, Article, and Disclosure InformationAffiliations: Heartlands Hospital and University of Birmingham, Birmingham, England, UK (I.D.)Harvard Medical School, Boston, Massachusetts, USA (A.K.S.)This article was published at Annals.org on 3 October 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDetermination of the probable time of myocardial infarction development in patients with type 2 diabetes mellitus 17 October 2017Volume 167, Issue 8Page: JC47KeywordsEnd stage kidney diseaseGlucoseMortalityMyocardial infarctionRenal diseasesRenal failureRenal transplantationRisk ratioType 1 diabetesType 2 diabetes ePublished: 17 October 2017 Issue Published: 17 October 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...